



Systane[®]
iLux²[®]

**Did you know meibomian gland
procedures are the fastest-growing
part of the dry eye market?¹**






The dry eye opportunity



Nearly **1 in 4 Canadians** suffer from dry eye.²



86% of dry eye patients have signs of Meibomian Gland Dysfunction (MGD).³



In the top 14 markets around the world, nearly 70% of dry eye patients are undiagnosed.¹



8 out of 10 doctors strongly agreed that “Treating dry eye patients can help my practice grow.”^{5**}

*Compound annual growth rate over 5 years.

**n=233 US ODs, MDs.




MGD: A disease of dysfunction


MGD is a chronic, progressive disease that's a contributing factor in 86% of dry eye cases.³ The disease is characterized by reduced meibum production/quality and meibomian gland dysfunction/atrophy.⁶ MGD contributes to tear film instability and breakup.⁶

Nearly 50% of MGD patients have no symptoms but will have signs of the disease.^{7,8} MGD symptoms include eye dryness, irritation, blurred vision and watery eyes.⁶

There is no permanent cure to MGD.
The goal of treatment is to help restore gland function.




MEIBOGRAPHY IMAGING OF MEIBOMIAN GLANDS




Artist rendering

CLEAR MEIBUM,
HEALTHY GLAND
SECRETION



Artist rendering

CLOUDY MEIBUM,
THICKENED SECRETION
AND SOME GLAND CAPPING



Artist rendering

INSPISSATED
MEIBUM,
SEVERE OBSTRUCTION



MGD patients are looking for answers



56%

of patients see four or more eye care providers in search of proper diagnosis and relief.⁹

\$853

One study suggests that, even for patients with mild dry eye, the average annual direct medical cost per patient is over \$800 per year.^{10*}

**MGD patients are already in your exam chair.
Be the hero they're looking for.**

*Based on a study where cost was \$678 USD and converted to Canadian dollar equivalent.



When you have MGD patients in your chair, how are you currently managing them?

TFOS DEWS II supports in-office thermal pulsation to treat MGD as early as step 2 in its DED management and treatment recommendations.¹¹

Clinical descriptions of MGD⁶

	STAGE 1	STAGE 2	STAGE 3	STAGE 4
LID MARGIN FEATURES	—	Scattered	Plugging, vascularity	Dropout, displacement
SECRETION ALTERATION	Minimally altered Grade >2 to 4	Mildly altered Grade >4 to <8	Moderately altered Grade >8 to <13	Severely altered Grade >13
EXPRESSIBILITY	1	1	2	3
STAINING	—	None-to-limited ocular surface staining	Mild-to-moderate conjunctival and peripheral corneal staining, often inferior	Increased conjunctival and corneal staining, including central staining
SIGNS OF INFLAMMATION	—	—	—	Moderate conjunctival hyperemia, phlyctenules



Enhance your surgical team's preoperative dry eye capabilities

Diagnosing and treating Ocular Surface Disease (OSD) before surgery may help you obtain more accurate data.¹²



Reduce signs and symptoms of MGD, which can affect measurements before cataract surgery¹³



Improve preoperative diagnostic measurement and refraction calculation accuracy¹⁴⁻¹⁶



Contribute to a healthy ocular surface which may make more patients eligible for Advanced Technology IOLs¹⁷



40% of the time the surgical plan was changed¹⁴



“If I diagnose MGD post-surgery—especially in a previously asymptomatic patient—the patient will likely perceive it as a result of surgery. If I diagnose it prior to surgery, then they take ownership.”

Ivan Mac, MD, MBA


Founder of Metrolina Eye Associates



Why Systane® iLux²® for MGD?

8-12 minute treatment.^{18,19}

12 month efficacy.²⁰



The all-in-one portable thermal pulsation and expression device can help diagnose and effectively treat MGD.



Systane® iLux²® delivers fast* treatment^{18,19} while allowing patients to visualize the need for the procedure



Educate patients on the need for treatment

Meibomian gland imaging that can be used to show patients a reason to believe in the value of MGD treatment.



Intuitive user experience and fast treatment

Total treatment in as little as 8 minutes.^{18,19*}



Personalized, portable and efficacious treatment

Customize heat and expression across each easy-to-visualize treatment zone.

*Treatment of both eyes using the Systane® iLux²® takes approximately 8-12 minutes.





Make the invisible visible

Seeing MGD in action may dramatically improve understanding and willingness to pay for treatment.

The **Systane® iLux²® MGD Thermal Pulsation System** offers imaging that can be used to view meibomian glands, make HD video of the procedure and to view treatment.

✓ **Direct visualization** boosts understanding of your treatment recommendation

✓ **Store meibomian gland images** to track disease over time





OPPORTUNITY

TECHNOLOGY

CLINICAL SUPPORT

POST TREATMENT



INFRARED IMAGING

WHITE LIGHT VIDEO



OPPORTUNITY

TECHNOLOGY

CLINICAL SUPPORT

POST TREATMENT



INFRARED IMAGING

WHITE LIGHT VIDEO




Does your current MGD care regimen yield this level of performance?



1-week post-treatment
Meibomian Gland Score (MGS)
increased on average by
315% versus baseline.^{21*}

iLux[®] treatments also resulted in **significant improvements in symptoms after one week**

Efficacy Endpoints	Change at 1 Week from Baseline
Meibomian gland assessment score (0-45)	OD: +11.6 ± 6.9 (p<0.0001) OS: +13.0 ± 7.3 (p<0.0001)
Tear Break-Up Time (seconds)	OD: +3.5 ± 2.7 (p<0.0001) OS: +3.7 ± 3.5 (p<0.0001)
SPEED Score	-8.6 ± 7.0 (p<0.0001)
OSDI Score	-26.3 ± 24.3 (p=0.0003)




*(P<0.0001). In a prospective, open-label, multicenter study of patients ≥18 years with MGD (n=30).



1 YEAR EFFICACY

Systane® iLux® was demonstrated to be **non-inferior to LipiFlow[^]** through 12 months (at all measurements, including 1, 3, 6, 9 months).²⁰



Prospective, randomized,
parallel group, investigator-
masked, **multi-center,**
12-month follow-up study



236 subjects
with meibomian
gland dysfunction


12 MONTHS RESULTS

[^]Trademarks are the property of their respective owners.




Non-inferiority over 12 months²⁰ with Systane® iLux®

Meibomian Gland Secretion Score Change over 12 Months*



MGS range 0-45 for 15 glands evaluated:
0 = No glands yielding secretion
45 = All glands yielding clear secretions

Change in Symptoms over 12 Months**



Symptom severity based on IDEEL-SB:
Green = None (0-16),
Yellow = Mild (17-38),
Orange = Moderate (39-65),
Red = Severe (66+)

Key Results

Non-inferiority of iLux® to LipiFlow[^] was demonstrated in change from Baseline **MGD scores** (95% LCL of the LSM difference >-0.5), and change in Baseline **IDEEL-SB module score** (95% UCL of the LSM difference <12).
Tear Film Stability (tear breakup time)²⁰ was also non-inferior to LipiFlow[^].

*Meibomian gland scores (0-45) measured using Meibomian Gland Evaluator to assess the 15 glands of the lower lid of each eye with a grade from 0-3.

**Impact of dry eye on every day life (IDEEL - SB) symptom bother score (with 20 questions).

[^]Trademarks are the property of their respective owners.

[^]Trademarks are the property of their respective owners.



Some Eye Care Practitioners know they want to do more for their dry eye patients, but need implementation support




The exclusive DEEP™ program provides the tools and expertise to help educate you and your staff in dry eye.

Ongoing professional Optometric consultation helps you expand your dry eye practice through:

1. Optimizing practice workflows
2. Communicating treatment recommendations to patients
3. Perfecting the ability of the user to effectively and quickly perform iLux²® treatments
4. Advising you and your clinic personnel on how to get the most out of the dry eye arm of your practice.



Systane® iLux²®: The most comprehensive offering

		Johnson & Johnson Lipiflow [^] Thermal Pulsation System	IPL (Intensive Pulse Light)
ECP ALWAYS IN CONTROL	✓	—	✓
FASTEST TREATMENT*	✓	—	—
IMAGING THAT CAN BE USED TO VIEW THE MEIBOMIAN GLANDS, HD IMAGING AND DISEASE TREATMENT	✓	—	—
HANDHELD PORTABLE	✓	—	—
HEAT AND EXPRESSION IN ONE DEVICE	✓	✓	—
ABILITY TO CUSTOMIZE TREATMENT IN REAL TIME AND ADD ADDITIONAL HEAT AND PRESSURE WHERE NECESSARY	✓	—	—
PATIENTS CAN CHOOSE TO HAVE EYE OPEN OR CLOSED DURING PROCEDURE	✓	—	—

*Including setup, treatment, expression and removal.

[^]Trademarks are the property of their respective owners.



Systane® iLux²®: The most comprehensive offering

	Systane® iLux ² ®	Heated Masks (Warm compresses)	Lid Scrubs (Foam or wipes)
IN-OFFICE 100% COMPLIANCE	✓	—	—
USE TIME	8-12 minutes	10-15 minutes, 1-2x per day, every day	1-2x per day, every day
STAFF TIME	8-12 minutes	8-10 minutes	8-10 minutes
LASTING RESULTS IN ONE WEEK	✓	—	—



Better together: Optimize post-treatment management with Systane® family of products



Systane® COMPLETE Preservative-Free offers instant and all day* symptom relief with just one drop²² and can be effectively used post-surgery and after iLux²® treatments. Recommend other Systane® products for help with post-treatment or postoperative dry eye and ocular hygiene management.

Help patients get the most out of their iLux²® treatments with Systane®



*8 hours.



IMPORTANT PRODUCT INFORMATION



Indication:

The Systane® iLux²® is indicated for the application of localized heat and pressure therapy in adult patients with meibomian gland dysfunction (MGD), which is associated with evaporative dry eye, and to capture/store digital images and video of the meibomian glands.

Contraindications:

Do NOT use the Systane® iLux²® in patients with the following conditions: Patients whose pupils have been pharmaceutically dilated; patients with ocular injury or trauma, chemical burns, or limbal stem cell deficiency (within prior 3 months); patients with active ocular herpes zoster or simplex of eye or eyelid or a history of these within prior 3 months; patients with cicatricial lid margin disease; patients with active ocular infection, active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months; patients with an ocular surface abnormality that may compromise corneal integrity; patients with lid surface abnormalities that affect lid function in either eye; patients with aphakia; or patients with permanent makeup or tattoos on their eyelids.

Warnings/Precautions:

Federal law restricts this device to sale by or on the order of a licensed healthcare practitioner.

The Disposable may not fit all eyes, such as eyes with small palpebral fornices. Use of the Systane® iLux²® is NOT recommended in patients with the following conditions: moderate to severe allergic, vernal or giant papillary conjunctivitis; severe eyelid inflammation; systemic disease conditions that cause dry eye; in patients who are taking medications known to cause dryness; patients with punctal plugs, or patients who have undergone ocular surgery within prior 3 months.

Potential Adverse Reactions:

Potential adverse effects may occur because of the procedure. These effects include but are not limited to, the onset or increase in: eyelid/eye pain requiring discontinuation of the treatment procedure, eyelid irritation or inflammation, temporary reddening of the skin, ocular surface irritation or inflammation (e.g., corneal abrasion, conjunctival edema or conjunctival injection (hyperemia), and ocular symptoms (e.g., burning, stinging, tearing, itching, discharge, redness, foreign body sensation, visual disturbance, sensitivity to light).

Attention: Please refer to the User Manual for a complete list of contraindications, instructions for use, warnings and precautions for the Systane® iLux²®.



References



1. MarketScope LLC. 2020 Dry Eye Products Report: A Global Market Analysis for 2019 to 2025. St. Louis, MO: MarketScope LLC; 2020.
2. Doughty MJ, Fonn D, Richter D, Simpson T, Caffery B, Gordon K. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. *Optom Vis Sci*. 1997;74(8):624-631.
3. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. *Cornea*. 2012;31:472-478.
4. Market Scope. 2018 Dry eye products report: a global market analysis for 2017 to 2023. Saint Louis, MO: Market Scope; November 2018.
5. Alcon data on file, 2018.
6. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. *Invest Ophthalmol Vis Sci*. 2011;52(4):1922-1929.
7. Cochener B, Cassan A, Omiel L. Prevalence of meibomian gland dysfunction at the time of cataract surgery. *J Cataract Refract Surg*. 2018;44(2):144-148.
8. Viso E, Rodríguez-Ares MT, Abelenda D, Oubiña B, Gude F. Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. *Invest Ophthalmol Vis Sci*. 2012;53(6):2601-2606.
9. The Dry Eye Problem. Building Your Dry Eye Center of Excellence. Review of Optometric Business supplement. <https://www.reviewob.com/building-your-dry-eye-center-of-excellence/>. Accessed July 13, 2021.
10. Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. *Cornea*. 2011;30(4):379-387.
11. Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. *Ocul Surf*. 2017;15:802-812.
12. Starr CE, Gupta PK, Farid M, et al. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. *J Cataract Refract Surg*. 2019;45(5):669-684.
13. Chuang J, Shih KC, Chan TC, Wan KH, Jhanji V, Tong L. Preoperative optimization of ocular surface disease before cataract surgery. *J Cataract Refract Surg*. 2017;43:1596-1607.
14. Matossian CA. Effect of thermal pulsation system treatment on keratometry measurements prior to cataract surgery. Paper presented at: 2019 American Society of Cataract and Refractive Surgery – American Society of Ophthalmic Administrators Annual Meeting; May 6, 2019; San Diego, CA.
15. Stephenson M. The relationship between dry eye and cataract surgery. Review of Ophthalmology. November 2017. <https://www.reviewofophthalmology.com/article/the-relationship-between-dry-eye-and-cataract-surgery>. Accessed December 10, 2019.
16. Epitropoulos AT, Matossian C, Berdy GJ, Malhotra RP, Potvin R. Effect of tear osmolarity on repeatability of keratometry for cataract surgery planning. *J Cataract Refract Surg*. 2015;41:1672-7.
17. Jordan L. Premium IOLs: how to spot poor candidates. Review of Ophthalmology. January 2018. <https://www.reviewofophthalmology.com/article/premium-iols-how-to-spot-poor-candidates>. Accessed December 10, 2019.
18. Tauber J, Owen J, Bloomenstein M, Hovanesian J, Bullimore MA. Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial. *Clin Ophthalmol*. 2020;14:405-418.
19. Alcon data on file, 2019.
20. Alcon data on file, 2021.
21. Geffen D, Yeh TN, Merchea MM. iLUX® efficacy after one week of treatment. Poster presented at: American Academy of Optometry 2020 Annual Meeting—Academy 2020 At Home; October 7-22, 2020; Nashville, TN.
22. Silverstein S, Yeu E, Tauber J, et al. Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial. *Clin Ophthalmol*. 2020;14:3167-3177.

©2022 Alcon Inc. CA-IL2-2200002